SIRT1 activates the expression of fetal hemoglobin genes

American Journal of Hematology

Volumn 92, Issue 11, 2017, Pages 1177-1186

  Dai, Yan ^a   Chen, Tyngwei ^a   Ijaz, Heba ^a   Cho, Elizabeth H ^a   Steinberg, Martin H ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD235A ANTIGEN; ENZYME ACTIVATOR; HEMOGLOBIN F; HEMOGLOBIN GAMMA CHAIN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; KRUPPEL LIKE FACTOR; KRUPPEL LIKE FACTOR 1; LYMPHOCYTE ANTIGEN; N [2 [3 (1 PIPERAZINYLMETHYL)IMIDAZO[2,1 B]THIAZOL 6 YL]PHENYL] 2 QUINOXALINECARBOXAMIDE; PROTEIN BCL 11A; PROTEIN BCL 2; RNA POLYMERASE II; SIRTUIN 1; SRT 2104; UNCLASSIFIED DRUG; MESSENGER RNA; PROTEIN BINDING;

ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; ECTOPIC EXPRESSION; ENZYME BINDING; ERYTHROBLAST; ERYTHROID CELL; ERYTHROID PRECURSOR CELL; GENE CLUSTER; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; K-562 CELL LINE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REGULATOR GENE; UMBILICAL CORD BLOOD; UPREGULATION; ANTIBODY SPECIFICITY; ERYTHROPOIESIS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; TRANSCRIPTION INITIATION;

CELL DIFFERENTIATION; CELL PROLIFERATION; ECTOPIC GENE EXPRESSION; ERYTHROBLASTS; ERYTHROID PRECURSOR CELLS; ERYTHROPOIESIS; FETAL HEMOGLOBIN; GAMMA-GLOBINS; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; K562 CELLS; LOCUS CONTROL REGION; ORGAN SPECIFICITY; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RNA, MESSENGER; SIRTUIN 1; TRANSCRIPTIONAL ACTIVATION;

EID: 85031490751     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24879     Document Type: Article

References (55)

1. Steinberg MH, Sebastiani P. Genetic modifiers of sickle cell disease. Am J Hematol. 2012;87:795–803.
2. Lettre G, Bauer DE. Fetal haemoglobin in sickle-cell disease: from genetic epidemiology to new therapeutic strategies. Lancet. 2016;387:2554–2564.
3. Noguchi CT, Rodgers GP, Serjeant G, Schechter AN. Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N Engl J Med. 1988;318:96–99.
4. Sankaran VG. Targeted therapeutic strategies for fetal hemoglobin induction. Hematology/the Education Program of the American Society of. Hematology Am Soc Hematol Educ Program. 2011;2011:459–465.
5. Bauer DE, Kamran SC, Orkin SH. Reawakening fetal hemoglobin: prospects for new therapies for the beta-globin disorders. Blood. 2012;120:2945–2953.
6. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol. 2010;85:403–408.
7. Sclafani S, Pecoraro A, Agrigento V, et al. Study on hydroxyurea response in hemoglobinopathies patients using genetic markers and liquid erythroid cultures. Hematol Rep. 2016;8:6678.
8. Rakotoson MG, Di Liberto G, Audureau E, et al. Biological parameters predictive of percent dense red blood cell decrease under hydroxyurea. Orphanet J Rare Dis. 2015;10:57.
9. Koenig SC, Becirevic E, Hellberg MS, et al. Sickle cell disease caused by heterozygosity for Hb S and novel LCR deletion: report of two patients. Am J Hematol. 2009;84:603–606.
10. Breda L, Motta I, Lourenco S, et al. Forced chromatin looping raises fetal hemoglobin in adult sickle cells to higher levels than pharmacologic inducers. Blood. 2016;128:1139–1143.
11. Deng W, Rupon JW, Krivega I, et al. Reactivation of developmentally silenced globin genes by forced chromatin looping. Cell. 2014;158:849–860.
12. Masuda T, Wang X, Maeda M, et al. Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin. Science (New York, NY). 2016;351:285–289.
13. Sankaran VG, Menne TF, Xu J, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science (New York, NY). 2008;322:1839–1842.
14. Shi L, Cui S, Engel JD, Tanabe O. Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction. Nat Med. 2013;19:291–294.
15. Bradner JE, Mak R, Tanguturi SK, et al. Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci U S A. 2010;107:12617–12622.
16. Aerbajinai W, Zhu J, Kumkhaek C, Chin K, Rodgers GP. SCF induces gamma-globin gene expression by regulating downstream transcription factor COUP-TFII. Blood. 2009;114:187–194.
17. Thein SL, Menzel S, Lathrop M, Garner C. Control of fetal hemoglobin: new insights emerging from genomics and clinical implications. Hum Mol Genet. 2009;18:R216–R223.
18. Rivers A, Vaitkus K, Ibanez V, et al. The LSD1 inhibitor RN-1 recapitulates the fetal pattern of hemoglobin synthesis in baboons (P. anubis). Haematologica. 2016;101:688–697.
19. Haigis MC, Guarente LP. Mammalian sirtuins–emerging roles in physiology, aging, and calorie restriction. Gene Dev. 2006;20:2913–2921.
20. Brooks CL, Gu W. How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer. 2009;9:123–128.
21. Dai Y, Faller DV. Transcription Regulation by Class III Histone Deacetylases (HDACs)-Sirtuins. Transl Oncogenomics. 2008;3:53–65.
22. Zhang T, Kraus WL. SIRT1-dependent regulation of chromatin and transcription: linking NAD(+) metabolism and signaling to the control of cellular functions. Biochim Biophys Acta. 2010;1804:1666–1675.
23. Brunet A, Sweeney LB, Sturgill JF, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science (New York, NY). 2004;303:2011–2015.
24. Donmez G, Wang D, Cohen DE, Guarente L. SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell. 2010;142:320–332.
25. Rajendran R, Garva R, Krstic-Demonacos M, Demonacos C. Sirtuins: molecular traffic lights in the crossroad of oxidative stress, chromatin remodeling, and transcription. J Biomed Biotechnol. 2011;2011:368276.
26. Xue Z, Lv X, Song W, et al. SIRT1 deacetylates SATB1 to facilitate MAR HS2-MAR epsilon interaction and promote epsilon-globin expression. Nucleic Acids Res. 2012;40:4804–4815.
27. Okam MM, Ebert BL. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors. Expert Rev Hematol. 2012;5:303–311.
28. Zhu L, Chiao CY, Enzer KG, Stankiewicz AJ, Faller DV, Dai Y. SIRT1 inactivation evokes antitumor activities in NSCLC through the tumor suppressor p27. Mol Cancer Res. 2015;13:41–49.
29. Dai Y, Sangerman J, Luo HY, et al. Therapeutic fetal-globin inducers reduce transcriptional repression in hemoglobinopathy erythroid progenitors through distinct mechanisms. Blood Cell Mol Dis. 2016;56:62–69.
30. van den Akker E, Satchwell TJ, Pellegrin S, Daniels G, Toye AM. The majority of the in vitro erythroid expansion potential resides in CD34(-) cells, outweighing the contribution of CD34(+) cells and significantly increasing the erythroblast yield from peripheral blood samples. Haematologica. 2010;95:1594–1598.
31. Mabaera R, Richardson CA, Johnson K, Hsu M, Fiering S, Lowrey CH. Developmental- and differentiation-specific patterns of human gamma- and beta-globin promoter DNA methylation. Blood. 2007;110:1343–1352.
32. Byles V, Zhu L, Lovaas JD, et al. SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene.31:4619–4629.
33. Kiefer CM, Lee J, Hou C, et al. Distinct Ldb1/NLI complexes orchestrate gamma-globin repression and reactivation through ETO2 in human adult erythroid cells. Blood. 2011;118:6200–6208.
34. van Steensel B, Dekker J. Genomics tools for unraveling chromosome architecture. Nat Biotechnol. 2010;28:1089–1095.
35. Hou C, Dale R, Dean A. Cell type specificity of chromatin organization mediated by CTCF and cohesin. Proc Natl Acad Sci U S A. 107:3651–3656.
36. Hoffmann E, Wald J, Lavu S, et al. Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man. Brit J Clin Pharmacol. 2013;75:186–196.
37. Vaziri H, Dessain SK, Ng Eaton E, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 2001;107:149–159.
38. Sakamoto J, Miura T, Shimamoto K, Horio Y. Predominant expression of Sir2alpha, an NAD-dependent histone deacetylase, in the embryonic mouse heart and brain. FEBS Lett. 2004;556:281–286.
39. Tobita T, Guzman-Lepe J, Takeishi K, et al. SIRT1 disruption in human fetal hepatocytes leads to increased accumulation of glucose and lipids. PloS One. 2016;11:e0149344.
40. Ogawa T, Wakai C, Saito T, et al. Distribution of the longevity gene product, SIRT1, in developing mouse organs. Congenit Anom (Kyoto). 2011;51:70–79.
41. McBurney MW, Yang X, Jardine K, Bieman M, Th'ng J, Lemieux M. The absence of SIR2alpha protein has no effect on global gene silencing in mouse embryonic stem cells. Mol Cancer Res. 2003;1:402–409.
42. Pace BS, Liu L, Li B, Makala LH. Cell signaling pathways involved in drug-mediated fetal hemoglobin induction: strategies to treat sickle cell disease. Exp Biol Med (Maywood). 2015;240:1050–1064.
43. Leberbauer C, Boulme F, Unfried G, Huber J, Beug H, Mullner EW. Different steroids co-regulate long-term expansion versus terminal differentiation in primary human erythroid progenitors. Blood. 2005;105:85–94.
44. Yuan H, Wang Z, Li L, et al. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood. 2012;119:1904–1914.
45. Leko V, Varnum-Finney B, Li H, et al. SIRT1 is dispensable for function of hematopoietic stem cells in adult mice. Blood. 2011;119:1856–1860.
46. Narala SR, Allsopp RC, Wells TB, et al. SIRT1 acts as a nutrient-sensitive growth suppressor and its loss is associated with increased AMPK and telomerase activity. Mol Biol Cell. 2008;19:1210–1219.
47. Ou X, Chae HD, Wang RH, et al. SIRT1 deficiency compromises mouse embryonic stem cell hematopoietic differentiation, and embryonic and adult hematopoiesis in the mouse. Blood. 2011;117:440–450.
48. Gallinari P, D, Marco S, Jones P, Pallaoro M, Steinkuhler C. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res. 2007;17:195–211.
49. Song SH, Hou C, Dean A. A positive role for NLI/Ldb1 in long-range beta-globin locus control region function. Mol Cell. 2007;28:810–822.
50. Deng W, Lee J, Wang H, et al. Controlling long-range genomic interactions at a native locus by targeted tethering of a looping factor. Cell. 2012;149:1233–1244.
51. Xu J, Sankaran VG, Ni M, et al. Transcriptional silencing of {gamma}-globin by BCL11A involves long-range interactions and cooperation with SOX6. Genes Dev. 2010;24:783–798.
52. Senawong T, Peterson VJ, Leid M. BCL11A-dependent recruitment of SIRT1 to a promoter template in mammalian cells results in histone deacetylation and transcriptional repression. Arch Biochem Biophys. 2005;434:316–325.
53. Rahim F, Allahmoradi H, Salari F, et al. Evaluation of signaling pathways involved in gamma-globin gene induction using fetal hemoglobin inducer drugs. Int J Hematol Oncol Stem Cell Res. 2013;7:41–46.
54. Salminen A, Kaarniranta K, Kauppinen A. Crosstalk between Oxidative Stress and SIRT1: impact on the aging process. Int J Mol Sci. 2013;14:3834–3859.
55. Schaeffer EK, West RJ, Conine SJ, Lowrey CH. Multiple physical stresses induce gamma-globin gene expression and fetal hemoglobin production in erythroid cells. Blood Cells, Mol Dis. 2014; 52:214–224.